Subchronic hepatotoxicity evaluation of bromobenzene in Fischer 344 rats

ABSTRACT Male Fischer 344 (F344) rats were exposed to bromobenzene (BB) for 5 days and 2, 4 and 13 weeks. BB was administered by gavage (corn oil vehicle) at doses of 0, 25, 100, 200, 300 and 400 mg kg−1 per day. Endpoints evaluated included clinical observations, body weights, liver weights, serum...

Full description

Saved in:
Bibliographic Details
Published in:Journal of applied toxicology Vol. 33; no. 5; pp. 370 - 377
Main Authors: Dodd, Darol E., Pluta, Linda J., Sochaski, Mark A., Banas, Deborah A., Thomas, Russell S.
Format: Journal Article
Language:English
Published: England Blackwell Publishing Ltd 01-05-2013
Wiley Subscription Services, Inc
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract ABSTRACT Male Fischer 344 (F344) rats were exposed to bromobenzene (BB) for 5 days and 2, 4 and 13 weeks. BB was administered by gavage (corn oil vehicle) at doses of 0, 25, 100, 200, 300 and 400 mg kg−1 per day. Endpoints evaluated included clinical observations, body weights, liver weights, serum chemistry, blood BB, gross pathology and liver histopathology. There were no BB exposure‐related clinical signs of toxicity. Mean body weight decreased by 5–10% compared with control in the 400 mg kg−1 per day group. Liver weight increases were dose‐ and exposure time‐related and statistically significant at ≥25 mg kg−1 per day. Incidence and severity of centrilobular cytoplasmic alteration and hepatocyte hypertrophy were related to dose and exposure time. At early time points (5 days and 2 weeks), centrilobular inflammation, including granulomatous areas, and necrotic and anisokaryocytic hepatocytes were observed in rats of the two highest BB dose groups. Blood BB concentrations increased linearly with dose and at 13 weeks ranged from 8 to 136 µg ml−1 (25–400 mg kg−1 per day). In conclusion, rats administered BB doses up to 400 mg kg−1 per day for up to 13 weeks had mild liver effects. A NOAEL of 200 mg kg−1 per day was selected based on the statistically significant incidence of hepatocyte hypertrophy at doses ≥ 400 mg kg−1 per day. Copyright © 2012 John Wiley & Sons, Ltd. Male Fischer 344 rats were administered bromobenzene by gavage at 0, 25, 100, 200, 300, or 400 mg kg−1 per day for 5 days and 2, 4 and 13 weeks. Mean body weight decreased 5‐10% at 400 mg kg−1 per day. Liver weight increases were dose‐ and exposure time‐related and significant at ≥25 mg kg−1 per day. Incidence and severity of centrilobular cytoplasmic alteration and hepatocyte hypertrophy were also related to dose and exposure time. A NOAEL of 200 mg kg−1 per day was selected based on a statistically significant increase in hypertrophy at ≥400 mg kg−1 per day.
AbstractList Male Fischer 344 (F344) rats were exposed to bromobenzene (BB) for 5days and 2, 4 and 13weeks. BB was administered by gavage (corn oil vehicle) at doses of 0, 25, 100, 200, 300 and 400mgkg-1 per day. Endpoints evaluated included clinical observations, body weights, liver weights, serum chemistry, blood BB, gross pathology and liver histopathology. There were no BB exposure-related clinical signs of toxicity. Mean body weight decreased by 5-10% compared with control in the 400mgkg-1 per day group. Liver weight increases were dose- and exposure time-related and statistically significant at ≥25mgkg-1 per day. Incidence and severity of centrilobular cytoplasmic alteration and hepatocyte hypertrophy were related to dose and exposure time. At early time points (5days and 2weeks), centrilobular inflammation, including granulomatous areas, and necrotic and anisokaryocytic hepatocytes were observed in rats of the two highest BB dose groups. Blood BB concentrations increased linearly with dose and at 13weeks ranged from 8 to 136µgml-1 (25-400mgkg-1 per day). In conclusion, rats administered BB doses up to 400mgkg-1 per day for up to 13weeks had mild liver effects. A NOAEL of 200mgkg-1 per day was selected based on the statistically significant incidence of hepatocyte hypertrophy at doses≥400mgkg-1 per day. Copyright © 2012 John Wiley & Sons, Ltd. Male Fischer 344 rats were administered bromobenzene by gavage at 0, 25, 100, 200, 300, or 400mgkg-1 per day for 5days and 2, 4 and 13weeks. Mean body weight decreased 5-10% at 400mgkg-1 per day. Liver weight increases were dose- and exposure time-related and significant at ≥25mgkg-1 per day. Incidence and severity of centrilobular cytoplasmic alteration and hepatocyte hypertrophy were also related to dose and exposure time. A NOAEL of 200mgkg-1 per day was selected based on a statistically significant increase in hypertrophy at ≥400mgkg-1 per day. [PUBLICATION ABSTRACT]
Male Fischer 344 (F344) rats were exposed to bromobenzene (BB) for 5days and 2, 4 and 13weeks. BB was administered by gavage (corn oil vehicle) at doses of 0, 25, 100, 200, 300 and 400mgkg super(-1) per day. Endpoints evaluated included clinical observations, body weights, liver weights, serum chemistry, blood BB, gross pathology and liver histopathology. There were no BB exposure-related clinical signs of toxicity. Mean body weight decreased by 5-10% compared with control in the 400mgkg super(-1) per day group. Liver weight increases were dose- and exposure time-related and statistically significant at greater than or equal to 25mgkg super(-1) per day. Incidence and severity of centrilobular cytoplasmic alteration and hepatocyte hypertrophy were related to dose and exposure time. At early time points (5days and 2weeks), centrilobular inflammation, including granulomatous areas, and necrotic and anisokaryocytic hepatocytes were observed in rats of the two highest BB dose groups. Blood BB concentrations increased linearly with dose and at 13weeks ranged from 8 to 136 mu gml super(-1) (25-400mgkg super(-1) per day). In conclusion, rats administered BB doses up to 400mgkg super(-1) per day for up to 13weeks had mild liver effects. A NOAEL of 200mgkg super(-1) per day was selected based on the statistically significant incidence of hepatocyte hypertrophy at doses greater than or equal to 400mgkg super(-1) per day. Copyright [copy 2012 John Wiley & Sons, Ltd. Male Fischer 344 rats were administered bromobenzene by gavage at 0, 25, 100, 200, 300, or 400mgkg super(-1) per day for 5days and 2, 4 and 13weeks. Mean body weight decreased 5-10% at 400mgkg super(-1) per day. Liver weight increases were dose- and exposure time-related and significant at greater than or equal to 25mgkg super(-1) per day. Incidence and severity of centrilobular cytoplasmic alteration and hepatocyte hypertrophy were also related to dose and exposure time. A NOAEL of 200mgkg super(-1) per day was selected based on a statistically significant increase in hypertrophy at greater than or equal to 400mgkg super(-1) per day.
Male Fischer 344 (F344) rats were exposed to bromobenzene (BB) for 5 days and 2, 4 and 13 weeks. BB was administered by gavage (corn oil vehicle) at doses of 0, 25, 100, 200, 300 and 400 mg kg(-1) per day. Endpoints evaluated included clinical observations, body weights, liver weights, serum chemistry, blood BB, gross pathology and liver histopathology. There were no BB exposure-related clinical signs of toxicity. Mean body weight decreased by 5-10% compared with control in the 400 mg kg(-1) per day group. Liver weight increases were dose- and exposure time-related and statistically significant at ≥25 mg kg(-1) per day. Incidence and severity of centrilobular cytoplasmic alteration and hepatocyte hypertrophy were related to dose and exposure time. At early time points (5 days and 2 weeks), centrilobular inflammation, including granulomatous areas, and necrotic and anisokaryocytic hepatocytes were observed in rats of the two highest BB dose groups. Blood BB concentrations increased linearly with dose and at 13 weeks ranged from 8 to 136 µg ml(-1) (25-400 mg kg(-1) per day). In conclusion, rats administered BB doses up to 400 mg kg(-1) per day for up to 13 weeks had mild liver effects. A NOAEL of 200 mg kg(-1) per day was selected based on the statistically significant incidence of hepatocyte hypertrophy at doses ≥ 400 mg kg(-1) per day.
Male Fischer 344 (F344) rats were exposed to bromobenzene (BB) for 5 days and 2, 4 and 13 weeks. BB was administered by gavage (corn oil vehicle) at doses of 0, 25, 100, 200, 300 and 400 mg kg −1 per day. Endpoints evaluated included clinical observations, body weights, liver weights, serum chemistry, blood BB, gross pathology and liver histopathology. There were no BB exposure‐related clinical signs of toxicity. Mean body weight decreased by 5–10% compared with control in the 400 mg kg −1 per day group. Liver weight increases were dose‐ and exposure time‐related and statistically significant at ≥25 mg kg −1 per day. Incidence and severity of centrilobular cytoplasmic alteration and hepatocyte hypertrophy were related to dose and exposure time. At early time points (5 days and 2 weeks), centrilobular inflammation, including granulomatous areas, and necrotic and anisokaryocytic hepatocytes were observed in rats of the two highest BB dose groups. Blood BB concentrations increased linearly with dose and at 13 weeks ranged from 8 to 136 µg ml −1 (25–400 mg kg −1 per day). In conclusion, rats administered BB doses up to 400 mg kg −1 per day for up to 13 weeks had mild liver effects. A NOAEL of 200 mg kg −1 per day was selected based on the statistically significant incidence of hepatocyte hypertrophy at doses ≥ 400 mg kg −1 per day. Copyright © 2012 John Wiley & Sons, Ltd. Male Fischer 344 rats were administered bromobenzene by gavage at 0, 25, 100, 200, 300, or 400 mg kg −1 per day for 5 days and 2, 4 and 13 weeks. Mean body weight decreased 5‐10% at 400 mg kg −1 per day. Liver weight increases were dose‐ and exposure time‐related and significant at ≥25 mg kg −1 per day. Incidence and severity of centrilobular cytoplasmic alteration and hepatocyte hypertrophy were also related to dose and exposure time. A NOAEL of 200 mg kg −1 per day was selected based on a statistically significant increase in hypertrophy at ≥400 mg kg −1 per day.
ABSTRACT Male Fischer 344 (F344) rats were exposed to bromobenzene (BB) for 5 days and 2, 4 and 13 weeks. BB was administered by gavage (corn oil vehicle) at doses of 0, 25, 100, 200, 300 and 400 mg kg−1 per day. Endpoints evaluated included clinical observations, body weights, liver weights, serum chemistry, blood BB, gross pathology and liver histopathology. There were no BB exposure‐related clinical signs of toxicity. Mean body weight decreased by 5–10% compared with control in the 400 mg kg−1 per day group. Liver weight increases were dose‐ and exposure time‐related and statistically significant at ≥25 mg kg−1 per day. Incidence and severity of centrilobular cytoplasmic alteration and hepatocyte hypertrophy were related to dose and exposure time. At early time points (5 days and 2 weeks), centrilobular inflammation, including granulomatous areas, and necrotic and anisokaryocytic hepatocytes were observed in rats of the two highest BB dose groups. Blood BB concentrations increased linearly with dose and at 13 weeks ranged from 8 to 136 µg ml−1 (25–400 mg kg−1 per day). In conclusion, rats administered BB doses up to 400 mg kg−1 per day for up to 13 weeks had mild liver effects. A NOAEL of 200 mg kg−1 per day was selected based on the statistically significant incidence of hepatocyte hypertrophy at doses ≥ 400 mg kg−1 per day. Copyright © 2012 John Wiley & Sons, Ltd. Male Fischer 344 rats were administered bromobenzene by gavage at 0, 25, 100, 200, 300, or 400 mg kg−1 per day for 5 days and 2, 4 and 13 weeks. Mean body weight decreased 5‐10% at 400 mg kg−1 per day. Liver weight increases were dose‐ and exposure time‐related and significant at ≥25 mg kg−1 per day. Incidence and severity of centrilobular cytoplasmic alteration and hepatocyte hypertrophy were also related to dose and exposure time. A NOAEL of 200 mg kg−1 per day was selected based on a statistically significant increase in hypertrophy at ≥400 mg kg−1 per day.
Author Pluta, Linda J.
Banas, Deborah A.
Thomas, Russell S.
Dodd, Darol E.
Sochaski, Mark A.
Author_xml – sequence: 1
  givenname: Darol E.
  surname: Dodd
  fullname: Dodd, Darol E.
  organization: The Hamner Institutes for Health Sciences, Research Triangle Park, NC, USA
– sequence: 2
  givenname: Linda J.
  surname: Pluta
  fullname: Pluta, Linda J.
  organization: The Hamner Institutes for Health Sciences, Research Triangle Park, NC, USA
– sequence: 3
  givenname: Mark A.
  surname: Sochaski
  fullname: Sochaski, Mark A.
  organization: The Hamner Institutes for Health Sciences, Research Triangle Park, NC, USA
– sequence: 4
  givenname: Deborah A.
  surname: Banas
  fullname: Banas, Deborah A.
  organization: Experimental Pathology Laboratories, Inc., Research Triangle Park, NC, USA
– sequence: 5
  givenname: Russell S.
  surname: Thomas
  fullname: Thomas, Russell S.
  email: Correspondence to: Russell Thomas, The Hamner Institutes for Health Sciences, Research Triangle Park, NC, USA., rthomas@thehamner.org
  organization: The Hamner Institutes for Health Sciences, Research Triangle Park, NC, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/22407932$$D View this record in MEDLINE/PubMed
BookMark eNqF0U1LHDEYwPEglrraQj-BDPTSy9jkSTJJjrL40rK2oJZKLyGZybDZziZrMtO6fnpncatQEE855MefJ3n20W6IwSH0geAjgjF8Xpj-CASFHTQhWKmSQEV30QRDhUtGxc0e2s95gfF4B_It2gNgWCgKE3R-Ndh6nmLwdTF3K9PHPt752vfrwv0x3WB6H0MR28KmuIzWhXsXXOFDcepzPXepoIwVyfT5HXrTmi6799vzAP04Pbmenpez72dfpsezsuYcoOTCNtjWjWENtMwoizkhQjELnBMpuOIEN7i1vKISZOtcI1RbCWANJYpLTg_Qp8fuKsXbweVeL8dJXNeZ4OKQNRGccsoIh9cpowqAMNhUP_5HF3FIYXzIRjEppaLqOVinmHNyrV4lvzRprQnWm0XocRF6s4iRHm6Dg1265gn--_kRlI_gr-_c-sWQ_np8vQ1uvc-9u3vyJv3WlaCC65_fzrScXdxcXv2a6gv6AMgKoAM
CitedBy_id crossref_primary_10_1021_acs_chemrestox_0c00387
crossref_primary_10_1007_s00204_016_1886_5
crossref_primary_10_1016_j_aquatox_2014_11_002
crossref_primary_10_1093_toxsci_kft249
Cites_doi 10.1093/mutage/2.2.111
10.1177/019262338501300404
10.1016/0272-0590(84)90241-0
ContentType Journal Article
Copyright Copyright © 2012 John Wiley & Sons, Ltd.
Copyright © 2013 John Wiley & Sons, Ltd.
Copyright_xml – notice: Copyright © 2012 John Wiley & Sons, Ltd.
– notice: Copyright © 2013 John Wiley & Sons, Ltd.
DBID BSCLL
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7ST
7TK
7U7
C1K
K9.
SOI
8FD
FR3
KR7
DOI 10.1002/jat.2732
DatabaseName Istex
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Environment Abstracts
Neurosciences Abstracts
Toxicology Abstracts
Environmental Sciences and Pollution Management
ProQuest Health & Medical Complete (Alumni)
Environment Abstracts
Technology Research Database
Engineering Research Database
Civil Engineering Abstracts
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
ProQuest Health & Medical Complete (Alumni)
Toxicology Abstracts
Neurosciences Abstracts
Environment Abstracts
Environmental Sciences and Pollution Management
Technology Research Database
Civil Engineering Abstracts
Engineering Research Database
DatabaseTitleList ProQuest Health & Medical Complete (Alumni)
Technology Research Database
Toxicology Abstracts
MEDLINE
CrossRef

Database_xml – sequence: 1
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Public Health
Pharmacy, Therapeutics, & Pharmacology
EISSN 1099-1263
EndPage 377
ExternalDocumentID 3079189101
10_1002_jat_2732
22407932
JAT2732
ark_67375_WNG_8LMXRSZC_M
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
.3N
.GA
.GJ
.Y3
05W
0R~
10A
1L6
1OB
1OC
1ZS
31~
33P
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52S
52T
52U
52W
52X
53G
5GY
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABEFU
ABEML
ABIJN
ABJNI
ABPVW
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFO
ACGFS
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFNX
AFFPM
AFGKR
AFPWT
AFRAH
AFZJQ
AHBTC
AHMBA
AI.
AIAGR
AITYG
AIURR
AIWBW
AJBDE
AJXKR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AUFTA
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMNLL
BMXJE
BNHUX
BROTX
BRXPI
BSCLL
BY8
CS3
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRSTM
EBD
EBS
EDH
EJD
F00
F01
F04
F5P
FEDTE
G-S
G.N
GNP
GODZA
GWYGA
H.T
H.X
HF~
HGLYW
HHZ
HVGLF
HZ~
IX1
J0M
JPC
KQQ
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
M6Q
MEWTI
MK4
MRFUL
MRSTM
MSFUL
MSSTM
MXFUL
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OIG
P2P
P2W
P2X
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
QRW
R.K
RIWAO
RJQFR
ROL
RWI
RX1
RYL
SAMSI
SUPJJ
UB1
V8K
VH1
W8V
W99
WBFHL
WBKPD
WH7
WIB
WIH
WIK
WJL
WOHZO
WQJ
WRC
WUP
WWP
WXSBR
WYISQ
XG1
XPP
XV2
YCJ
YHZ
ZXP
ZZTAW
~02
~IA
~KM
~WT
CGR
CUY
CVF
ECM
EIF
NPM
AAMNL
AAYXX
CITATION
7ST
7TK
7U7
C1K
K9.
SOI
8FD
FR3
KR7
ID FETCH-LOGICAL-c5522-57bd0bcda4d2f4a9b0511794b25518759510d0fb563828feed79f6724d3195853
IEDL.DBID 33P
ISSN 0260-437X
IngestDate Fri Aug 16 09:57:03 EDT 2024
Fri Aug 16 07:14:19 EDT 2024
Thu Oct 10 22:22:04 EDT 2024
Thu Nov 21 20:50:18 EST 2024
Sat Sep 28 08:06:53 EDT 2024
Sat Aug 24 01:18:06 EDT 2024
Wed Oct 30 09:52:57 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 5
Language English
License Copyright © 2012 John Wiley & Sons, Ltd.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5522-57bd0bcda4d2f4a9b0511794b25518759510d0fb563828feed79f6724d3195853
Notes ark:/67375/WNG-8LMXRSZC-M
ArticleID:JAT2732
istex:442A8DE7030EE145EDCC4C219B7A6E0A992DACCC
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 22407932
PQID 1434888939
PQPubID 105373
PageCount 8
ParticipantIDs proquest_miscellaneous_1753534152
proquest_miscellaneous_1439221425
proquest_journals_1434888939
crossref_primary_10_1002_jat_2732
pubmed_primary_22407932
wiley_primary_10_1002_jat_2732_JAT2732
istex_primary_ark_67375_WNG_8LMXRSZC_M
PublicationCentury 2000
PublicationDate May 2013
PublicationDateYYYYMMDD 2013-05-01
PublicationDate_xml – month: 05
  year: 2013
  text: May 2013
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: Bognor Regis
PublicationSubtitle JAT
PublicationTitle Journal of applied toxicology
PublicationTitleAlternate J. Appl. Toxicol
PublicationYear 2013
Publisher Blackwell Publishing Ltd
Wiley Subscription Services, Inc
Publisher_xml – name: Blackwell Publishing Ltd
– name: Wiley Subscription Services, Inc
References Final Rules: Animal Welfare Standards; 9 CFR Part 3. 15 February 1991. Fed. Reg. 55(32): 6426-6505.
US EPA. 1998. Health Effects Test Guidelines. OPPTS 870.3100 90-Day Oral Toxicity in Rodents. EPA 712-C-98-199. US Environmental Protection Agency: Washington, DC.
Colacci A, Arfellini G, Mazzullo M, Prodi G, Grilli S. 1985. The covalent binding of bromobenzene with nucleic acids. Toxicol. Pathol. 13: 276-282.
Final Rules: Animal Welfare; 9 CFR Parts 1 and 2. 31 August 1989. Fed. Reg. 54(168): 36112-36163.
NRC. 1996. Guide for the Care and Use of Laboratory Animals. The National Academies Press: Washington, DC.
Kluwe WM, Maronpot RR, Greenwell A, Harrington F. 1984. Interactions between bromobenzene dose, glutathione concentrations, and organ toxicities in single- and multiple-treatment studies. Fundam. Appl. Toxicol. 4: 1019-1028.
US EPA. 2005. Guidelines for Carcinogen Risk Assessment. EPA/630/P-03/001B. Risk Assessment Forum, US Environmental Protection Agency: Washington, DC.
Mohtashamipur E, Triebel R, Straeter H, Norpoth K. 1987. The bone marrow clastogenicity of eight halogenated benzenes in male NMRI mice. Mutagenesis 2(2): 111-113.
US EPA. 1984. Health and Environmental Effects Profile for Bromobenzenes. EPA/600/X-84/128 (NTIS PB88137757). US Environmental Protection Agency: Washington, DC.
1987; 2
1989; 54
1984; 4
1991; 55
1981b
1981a
1985b
1976
1998
2009
1985a
1986
1996
1985d
1985c
1984
2005
1985; 13
US EPA (e_1_2_6_17_1) 1984
Final Rules: Animal Welfare Standards (e_1_2_6_4_1) 1991; 55
e_1_2_6_9_1
e_1_2_6_8_1
NRC (e_1_2_6_10_1) 1996
e_1_2_6_5_1
e_1_2_6_7_1
e_1_2_6_6_1
e_1_2_6_13_1
e_1_2_6_14_1
e_1_2_6_11_1
US EPA (e_1_2_6_20_1) 2009
e_1_2_6_2_1
Final Rules: Animal Welfare (e_1_2_6_3_1) 1989; 54
e_1_2_6_12_1
US EPA (e_1_2_6_18_1) 1998
e_1_2_6_15_1
e_1_2_6_16_1
US EPA (e_1_2_6_19_1) 2005
References_xml – year: 1986
– year: 2009
– year: 1984
– year: 1985c
– year: 1985b
– year: 1985d
– volume: 54
  start-page: 36112
  issue: 168
  year: 1989
  end-page: 36163
  article-title: 9 CFR Parts 1 and 2
  publication-title: Fed. Reg.
– year: 2005
– year: 1985a
– year: 1981b
– year: 1981a
– volume: 55
  start-page: 6426
  issue: 32
  year: 1991
  end-page: 6505
  article-title: 9 CFR Part 3
  publication-title: Fed. Reg.
– year: 1996
– volume: 13
  start-page: 276
  year: 1985
  end-page: 282
  article-title: The covalent binding of bromobenzene with nucleic acids
  publication-title: Toxicol. Pathol.
– volume: 4
  start-page: 1019
  year: 1984
  end-page: 1028
  article-title: Interactions between bromobenzene dose, glutathione concentrations, and organ toxicities in single‐ and multiple‐treatment studies
  publication-title: Fundam. Appl. Toxicol.
– volume: 2
  start-page: 111
  issue: 2
  year: 1987
  end-page: 113
  article-title: The bone marrow clastogenicity of eight halogenated benzenes in male NMRI mice
  publication-title: Mutagenesis
– year: 1976
– year: 1998
– ident: e_1_2_6_5_1
– volume-title: Guidelines for Carcinogen Risk Assessment
  year: 2005
  ident: e_1_2_6_19_1
  contributor:
    fullname: US EPA
– volume-title: Health and Environmental Effects Profile for Bromobenzenes
  year: 1984
  ident: e_1_2_6_17_1
  contributor:
    fullname: US EPA
– volume-title: Support of Summary Information on the Integrated Risk Information System (IRIS)
  year: 2009
  ident: e_1_2_6_20_1
  contributor:
    fullname: US EPA
– ident: e_1_2_6_13_1
– ident: e_1_2_6_16_1
– ident: e_1_2_6_11_1
– ident: e_1_2_6_14_1
– volume: 54
  start-page: 36112
  issue: 168
  year: 1989
  ident: e_1_2_6_3_1
  article-title: 9 CFR Parts 1 and 2
  publication-title: Fed. Reg.
  contributor:
    fullname: Final Rules: Animal Welfare
– ident: e_1_2_6_9_1
  doi: 10.1093/mutage/2.2.111
– volume-title: Guide for the Care and Use of Laboratory Animals
  year: 1996
  ident: e_1_2_6_10_1
  contributor:
    fullname: NRC
– ident: e_1_2_6_2_1
  doi: 10.1177/019262338501300404
– ident: e_1_2_6_6_1
– ident: e_1_2_6_8_1
  doi: 10.1016/0272-0590(84)90241-0
– ident: e_1_2_6_7_1
– ident: e_1_2_6_15_1
– volume-title: Health Effects Test Guidelines. OPPTS 870.3100 90‐Day Oral Toxicity in Rodents
  year: 1998
  ident: e_1_2_6_18_1
  contributor:
    fullname: US EPA
– volume: 55
  start-page: 6426
  issue: 32
  year: 1991
  ident: e_1_2_6_4_1
  article-title: 9 CFR Part 3
  publication-title: Fed. Reg.
  contributor:
    fullname: Final Rules: Animal Welfare Standards
– ident: e_1_2_6_12_1
SSID ssj0009928
Score 2.0849123
Snippet ABSTRACT Male Fischer 344 (F344) rats were exposed to bromobenzene (BB) for 5 days and 2, 4 and 13 weeks. BB was administered by gavage (corn oil vehicle) at...
Male Fischer 344 (F344) rats were exposed to bromobenzene (BB) for 5 days and 2, 4 and 13 weeks. BB was administered by gavage (corn oil vehicle) at doses of...
Male Fischer 344 (F344) rats were exposed to bromobenzene (BB) for 5days and 2, 4 and 13weeks. BB was administered by gavage (corn oil vehicle) at doses of 0,...
SourceID proquest
crossref
pubmed
wiley
istex
SourceType Aggregation Database
Index Database
Publisher
StartPage 370
SubjectTerms Administration, Oral
Alterations
Animals
Blood
Body weight
Body Weight - drug effects
bromobenzene
Bromobenzenes - toxicity
Corn Oil - chemistry
Dosage
dose-response
Dose-Response Relationship, Drug
Endpoint Determination
Hepatocytes - drug effects
hepatotoxicity
Hydrocarbons
Incidence
Liver
Liver - drug effects
Liver - metabolism
Male
Males
No-Observed-Adverse-Effect Level
Organ Size - drug effects
Rats
Rats, Inbred F344
Rodents
time course
Toxicity
Toxicity Tests, Subchronic
Title Subchronic hepatotoxicity evaluation of bromobenzene in Fischer 344 rats
URI https://api.istex.fr/ark:/67375/WNG-8LMXRSZC-M/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjat.2732
https://www.ncbi.nlm.nih.gov/pubmed/22407932
https://www.proquest.com/docview/1434888939
https://search.proquest.com/docview/1439221425
https://search.proquest.com/docview/1753534152
Volume 33
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Nb9QwELVKe0FCUAq0S1tkJLSnhmb9sUl6q9oue6DVihax4mL5IxZLpQQ1u1LbX98Ze7NRJUBInHKIozj2vJk3jueZkA-WW5dyDsZb5joRNisTPfA-GXJRDpiTAx8W3MaX2cU0Pz1DmZyjthYm6kOsFtwQGcFfI8C1aQ470dCfev4RYi-6X0gSQvUGn3R6u0U4VhUVsxLBs2mrO5uyw_bBR5FoAwf19nc08zFrDWFn9OJ_OrxJni_JJj2O1vGSrJXVFulPolr13QG96oqvmgPap5NOx_puizyLS3o0Viq9ImNwMjZq6dIfEMXm9by-nVmg8bTTDKe1pwa3-Jmyugc_SmcVHc0aNA3KhaBgcM1r8nV0dnUyTpYHMSRWSkxWM-NSY50WjnmhCwNIRiAbhnpumUSW5lJvJICZ5R7Cblb4YcaE46hlI_kbsl7VVblDqPPWCQycUgjUzSlMrj2woNw7O_Qs7ZH37aSoX1FvQ0VlZaZgABUOYI_0w2ytGuiba9yflkn17eKTyj-fT79cfj9R5z2y106nWkKzgVyHg9MCmlbAu1a3AVT4p0RXZb0IbQqGYnTyL20g0ZMc-U-PbEdTWXUo5MlF6GmwiD9-igInjNe3_9pwlzxl4UAO3HK5R9bnN4tynzxp3OJdAMAD0VoFdg
link.rule.ids 315,782,786,1408,27933,27934,46064,46488
linkProvider Wiley-Blackwell
linkToHtml http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9NAEB5BewAJUSivQIFFQjnV1NlHbKunqm0IIokiGkTUy8r2etUUyUZ1IrX8emZ241iVACFx8sFjeb07j2_GO98CvM9FbkIhUHmLOA1kHhVB2rM26AtZ9LhRPesKbsOzaDKPT06JJuew6YXx_BCbghtZhvPXZOBUkD5oWUMv0-UHDL7of7dlH_WQ-jfEtGXcTdzBqsSZFUgRzRvm2ZAfNE_eikXbNK3XvwOat3GrCzyDnf8a8iN4uMab7MgryGO4U5S70J16wuqbfTZr-6_qfdZl05bK-mYXHviqHvPNSk9giH4m93S67AID2bJaVteLHJE8a2nDWWVZRrv8sqL8ia6ULUo2WNSkHUxIyVDn6qfwdXA6Ox4G67MYglwpylejzIRZblJpuJVpkqExky1nnCjdIkVAzYQ2U2jPPLYYeaPE9iMujSA6GyWewVZZlcULYMbmRlLsVFISdU6SxalFIBRbk_ctDzvwrlkV_cNTbmhPrsw1TqCmCexA1y3XRiC9-k5b1CKlv00-6ng0nn85Oz_W4w7sNeup19ZZY7ojUF8QqSX4rs1ttCv6WZKWRbVyMgknPjr1FxnM9ZQgCNSB515XNgNyqXLiRupU4o-fotEP0_Xlvwq-hXvD2XikR58mn1_Bfe7O56AdmHuwtbxaFa_hbm1Wb5w1_AJRzQme
linkToPdf http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpZ3bb9MwFIePYJMQEuIyboUBRkJ9WljqS5PwhraVIraqYkNUe7ESO9Y6pGRaWmnjr-ccu2k0CRAST3mIozj2ufzs2J8B3hlhbCwEGm-Z5pE0SRnlA-eioZDlgFs1cH7CbXycTGbp_gFhcj60e2ECH2I94Uae4eM1OfiFdbsdNPQ8X7zH3Ivhd1OiCiduvhDTDrib-XNVCZkVSZHMWvBszHfbJ2-kok1q1avf6cybstXnndGD_6nxQ7i_UpvsYzCPR3CrrLagPw246usddtLtvmp2WJ9NO5D19RbcC3N6LGxVegxjjDImwHTZGaaxRb2or-YGdTzroOGsdqygNX5FWf3EQMrmFRvNG7INJqRkaHHNE_g2OjjZG0erkxgioxSNVpPCxoWxubTcyTwr0JXJkwtOQLdEkUyzsSsUejNPHebdJHPDhEsrCGajxFPYqOqqfA7MOmMlZU4lJYFzsiLNHcqg1FkzdDzuwdu2U_RFAG7ogFbmGhtQUwP2oO97a10gv_xBC9QSpb9PPun08Gj29fh0Tx_1YLvtTr3yzQYHOwKjFuq0DN-1vo1eRb9K8qqsl75MxolGp_5SBkd6SpAA6sGzYCrrCvmBcuZr6i3ij5-iMQrT9cW_FnwDd6b7I334efLlJdzl_nAOWn65DRuLy2X5Cm43dvna-8IvC6UIRA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Subchronic+hepatotoxicity+evaluation+of+bromobenzene+in+Fischer+344+rats&rft.jtitle=Journal+of+applied+toxicology&rft.au=Dodd%2C+Darol+E.&rft.au=Pluta%2C+Linda+J.&rft.au=Sochaski%2C+Mark+A.&rft.au=Banas%2C+Deborah+A.&rft.date=2013-05-01&rft.issn=0260-437X&rft.eissn=1099-1263&rft.volume=33&rft.issue=5&rft.spage=370&rft.epage=377&rft_id=info:doi/10.1002%2Fjat.2732&rft.externalDBID=10.1002%252Fjat.2732&rft.externalDocID=JAT2732
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0260-437X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0260-437X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0260-437X&client=summon